Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504693 | 0.98 | HDAC1 (0.68) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5504688 | 0.98 | HDAC1 (0.68) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5509133 | 0.95 | HDAC1 (0.62) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL23049765 | 0.84 | HDAC1 (0.67) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL5849402 | 0.84 | HDAC1 (0.67) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL26135918 | 0.83 | MMP1 (0.76) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL2091453 | 0.83 | HDAC1 (0.65) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL4100412 | 0.83 | HDAC1 (0.69) | HDAC1HDAC8MMP1PTPN1GSK3B | |
| SCHEMBL10471481 | 0.83 | NPC1 (0.53) | HDAC1HDAC8NPC1RAB9AMAPT | |
| SCHEMBL739090 | 0.83 | HDAC1 (0.69) | HDAC1HDAC8MMP1PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828161-A2 | PHENYLPIPERAZINES WITH A COMBINATION OF AFFINITY FOR DOPAMINE -D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | Solvay Pharmaceuticals B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| WO-2006061372-A2 | PHENYLPIPERAZINES WITH A COMBINATION OF AFFINITY FOR DOPAMINE -D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
| US-20060122177-A1 | Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| CN-1671386-A | Substituted anilinic piperidines as MCH selective antagonists | LUNDBECK & CO AS H (DK) | 2005-09-21 | — | — | CN | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | HDAC1 3125/4885HDAC8 3891/4885MMP1 2463/4885 |
| US-20060122177-A1 | Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | HTR2A, HTR2C, HTR5A | HDAC1 3211/4885HDAC8 4093/4885MMP1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.